Your data on MRCVSonline
The nature of the services provided by Vision Media means that we might obtain certain information about you.
Please read our Data Protection and Privacy Policy for details.

In addition, (with your consent) some parts of our website may store a 'cookie' in your browser for the purposes of
functionality or performance monitoring.
Click here to manage your settings.
If you would like to forward this story on to a friend, simply fill in the form below and click send.

Your friend's email:
Your email:
Your name:
 
 
Send Cancel

Earlier treatment 'could delay onset of heart failure'
dog
Lead author Adrian Boswood, professor of veterinary cardiology at the RVC, said thanks to the findings, vets no longer have to adopt a 'watch and wait' approach with suspected preclinical cases of MVD.
RVC: Study highlights need for shift in treatment of preclinical MVD
 
A new study suggests earlier treatment of preclinical mitral valve disease (MVD) can delay the onset of heart failure in dogs. Researchers from the Royal Veterinary College (RVC) say this highlights the need for a shift in the way vets diagnose and manage the disease.

The study, Evaluation of Pimobendan in Cardiomegaly (EPIC), found the drug was able to extend the asymptomatic period by 15 months on average and dogs that received pimobendan lived significantly longer than those receiving a placebo. The findings have been published in the Journal of Veterinary Internal Medicine.

Heart disease is one of the top five causes of death in UK dogs and MVD accounts for 75 per cent of cases.

Lead author Adrian Boswood, professor of veterinary cardiology at the RVC, said thanks to the findings, vets no longer have to adopt a 'watch and wait' approach with suspected preclinical cases of MVD.

"When a typical mitral valve murmur is detected, vets should now investigate further to look for cardiac enlargement. If demonstrated, this suggests the patient will probably benefit from treatment with pimobendan before the onset of clinical signs."

Researchers say the EPIC study, which was designed and run by an independent team and sponsored by Boehringer Ingelheim, is the largest prospective veterinary cardiology study carried out to date and produced data to rival that of human clinical trials. Taking seven years to complete, it involved 360 dogs across 11 countries in four continents.

In light of the findings, the team say vets should now consider testing early for signs of preclinical MVD, and in dogs with cardiomegaly secondary to preclinical MVD, should consider the use of pimobendan to delay the onset of congestive heart failure and extend the asymptomatic period.
 

Image courtesy of RVC

Become a member or log in to add this story to your CPD history

Equine Disease Surveillance report released for Q4 2025

News Story 1
 The latest Equine Disease Surveillance report has been released, with details on equine disease from Q4 of 2025.

The report, produced by Equine Infectious Disease Surveillance, includes advice on rule changes for equine influenza vaccination.

Statistics and maps detail recent outbreaks of equine herpes virus, equine influenza, equine strangles and equine grass sickness. A series of laboratory reports provides data on virology, bacteriology, parasitology and toxicosis.

This issue also features a case study of orthoflavivus-associated neurological disease in a horse in the UK. 

Click here for more...
News Shorts
NSA webinar explores sheep tailing and castration

The National Sheep Association (NSA) is to host a free webinar on the castration and tail docking of lambs.

The webinar, 'Understanding the tailing and castration consultation: A guide for sheep farmers', will be hosted online on Monday, 2 March 2026 at 7.30pm.

It comes during a government consultation into the methods used for these procedures. Farmers are encouraged to engage before the consultation period closes on Monday, 9 March 2026.

The webinar offers clear and actionable guidance to support farmers to contribute meaningfully to the consultation and prepare for potential changes.

On the panel will be former SVS president Kate Hovers, farmer and vet Ann Van Eetvelt and SRUC professor in Animal Health and Veterinary Sciences Cathy Dwyer. Each panel member will utilise their own specialism and expertise to evaluate risks and outcomes to sheep farming.

Find out more about the webinar on the NSA website.